Emerging therapies for gout

Expert Opinion on Emerging Drugs

Volumn 17, Issue 4, 2012, Pages 511-518

  Singh, Jasvinder A ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

Canakinumab; Emerging therapies; Gout; Hyperuricemia; Lesinurad; Rilonacept

Indexed keywords

ALLOPURINOL; BENZBROMARONE; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; GLUCOCORTICOID; INDOMETACIN; INTERLEUKIN 1; LESINURAD; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PROBENECID; RILONACEPT; SULFINPYRAZONE; TRANILAST; TRIAMCINOLONE; ULODESINE; URATE; URIC ACID;

ABDOMINAL WALL HERNIA; APPENDICITIS; BRONCHITIS; CAROTID ARTERY OBSTRUCTION; CORONARY ARTERY DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GOUT; HEART INFARCTION; HUMAN; HYPERURICEMIA; INJECTION SITE REACTION; KIDNEY; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; LIVER ABSCESS; LOADING DRUG DOSE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRESCRIPTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URIC ACID URINE LEVEL; VISUAL ANALOG SCALE; WEIGHT GAIN;

ADULT; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DRUG DESIGN; GOUT; GOUT SUPPRESSANTS; HUMANS; INFLAMMATION; QUALITY OF LIFE;

EID: 84870453022     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.736488     Document Type: Review

References (37)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011;63(10):3136-41
2. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health related quality of life and higher health care utilization in US veterans. Ann Rheum Dis 2008;67(9):1310-16
3. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007;46(9):1441-4
4. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1312-24
5. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65(10):1301-11
6. Khanna D, Khanna PP, Fitzgerald JD, et al. American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012;64(10):1447-61
7. Khanna D, Fitzgerald JD, Khanna PP, et al. American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64(10):1431-46
8. Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005;44(8):1038-42
9. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007;57(5):822-9
10. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51(3):321-5
11. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68(8):1265-70
12. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81(7):925-34
13. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25(6):1593-617
14. Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother 2011;9(5):271-85
15. Hoskison TK, Wortmann RL. Advances in the management of gout and hyperuricaemia. Scand J Rheumatol 2006;35(4):251-60
16. Keenan RT, ÓBrien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124(2):155-63
17. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68(10):1613-17
18. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64(3):876-84
19. Schumacher HR Jr, Evans RR, Saag KG, et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results of the presurge-1 trial. Arthritis Care Res (Hoboken) 2012;64(10):1462-70
20. Mitha E, Fouche L, Wang J, et al. Evaluation of Rilonacept for prevention of gout flares during initiation of uric acid loweing therapy: results of a phase 3, randomized, double-blind, palcebo-controlled glocal trial. Ann Rheum Dis 2011;70(Suppl 3):168
21. Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor Teleconference. 2010. Available from: http://files.shareholder.com/downloads/REGN/941483174x0x380925/ e99d3c78-f180-4597-a98d-fc1ce20abe49/REGN-ilonacept-all-resentation.pdf [Cited 20 August 2012]
22. Sundy JS, Schumacher HR, Kirstein J, et al. Rilonacept for gout flare prevention in patients on uric acid-lowering therapy: results of a double-blind, placebo-controlled, phase 3, international safety study. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1013
23. Sundy JS, Schumacher HR, Kirstein J, et al. Rilonacept for gout flare prevention: subgroup analysis of patients initiating or continuing uric acid-lowering therapy in a randomized, placebo-controlled trial. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1023
24. Schumacher HR, Evans RR, Birbara CA, et al. Rilonacept for prevention of gout flares associated with uric acid-lowering therapy: response rate across three phase 3 clinical trials. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1024
25. FDA rejects Rejects Rilonacept for Treatment of Gout Flares. Available from: http://www.topix.com/forum/health/gout/TL96I9O22H657DGUC
26. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10(3):R67
27. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62(10):3064-76
28. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011;13(2):R53
29. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; Epub ahead of print
30. Arthritis Advisory Committee Meeting, June 21, 2011. FDA Briefing Document. Supplemental BLA 125319: Ilaris (canakinumab) for the following proposed indication: "ILARIS is indicated for the treatment of gouty arthritis attacks. ILARIS has also been shown to extend the time to the next attack and reduce the frequency of subsequent attacks". Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM259596.pdf
31. Lasko B, Sheedy B, Hingorani V, et al. RDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients [abstract]. Arthritis Rheum 2009;60(Suppl):1105
32. Perez-Ruiz F, Sundy JS, Krishnan E, et al. Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: randomized, doubl-blind, placebo-controlled, phase 2b study. [abstract]. Ann Rheum Dis 2011;70(Suppl 3):104
33. Perez-Ruiz F, Sundy JS, Krishnan E, et al. Efficacy and safety of lesinurad (RDEA594), a novel uricosuric agent, in combination with allopurinol in gout patients with an inadequate response to allopurinol: results from the randomized, blinded, placebo-controlled, phase 2B extension study. [abstract]. Ann Rheum Dis 2012;71(Suppl 3):439
34. Hagerty D, Kerr B, Shen Z, et al. Pharmacokinetics, efficacy and safety of lesinurad, a novel URAT1 inhibitor, in individuals with mild to moderate renal impairment [abstract]. Arthritis Rheum 2011;63(Suppl 10):1030
35. Fleischman RM, Shen Z, Yeh LT, et al. Lesinurad (RDEA594), a novel uricosuric agent, in combination with with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens. [abstract]. Ann Rheum Dis 2011;70(Suppl 3):188
36. Fitz-Patrick D, Drummond W, Pappas J, Hollister AS. Effects of a purine nucleoside phosphorylase inhibitor, bcx4208, on the serum uric acid concentrations in patients with gout [abstract]. Arthritis & Rheumatism 2010;62(Suppl 10):150
37. Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21(10):1157-62